We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.50 | 22.20 | 25.00 | 4,000 | 08:00:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.95 | 18.16M |
TIDMONC
RNS Number : 2173V
Oncimmune Holdings PLC
05 April 2019
5 April 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune Announces EarlyCDT(R) -Lung Kit Distribution Agreement for Portugal and Extends Agreement for Spain
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that it has signed an exclusive agreement for the distribution of its EarlyCDT-Lung test kit in Portugal with Sabartech S.L. ("Sabartech"), its existing distributor in Spain. The agreement includes a minimum sales commitment of GBP700,000 over 5 years.
Every year in Portugal approximately 5,300 new cases are diagnosed and approximately 4,700 deaths occur from lung cancer. Lung cancer is the largest cause of cancer-related deaths in Portugal.
Oncimmune has also extended Sabartech's agreement in Spain from three to five years, in light of the excellent progress made including the recently secured agreement to sell EarlyCDT-Lung as a screening test for the early detection of lung cancer through the hospitals and clinics of the Quirónsalud group ("Quirónsalud"). The extension adds a further GBP1.8 million of minimum sales commitments over years 4 and 5.
Dr Adam M Hill, CEO of Oncimmune commented: "Portugal and Spain are important European markets and Sabartech has made good progress so far including selling EarlyCDT-Lung for screening through Quirónsalud, the largest private hospital network in Spain. Extending our relationship to include Portugal was a natural progression and marks another step in the commercialisation of EarlyCDT-Lung."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Mike Seabrook
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5700
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
AGRCKQDDDBKBNQK
(END) Dow Jones Newswires
April 05, 2019 02:01 ET (06:01 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions